By Fineline Cube BriSTAR Immunotech (Beijing) Co., Ltd. announced the completion of a Series C financing round exceeding RMB 200 million (approximately $28 million), led by Loyal Valley Capital with participation from Fudan Science and Technology Innovation, to accelerate clinical development and commercialization of its proprietary STAR-T cell therapy platform.
Financing Details & Strategic Allocation
| Component | Detail |
|---|---|
| Round | Series C |
| Amount | Over RMB 200 million (~$28 million) |
| Lead Investor | Loyal Valley Capital |
| Participating Investor | Fudan Science and Technology Innovation |
| Primary Use of Funds | Registration clinical development of YTS109 (lead product); In vivo STAR-T platform construction; commercialization system establishment; global IP portfolio expansion |
Company Profile & Technology Platforms
- Founded: 2018
- Core Focus: Research, development, and commercialization of STAR-T technology and general-purpose site-specific integration technology platform
- Technology Portfolio:
- STAR-T Technology Platform – proprietary T-cell receptor engineering approach
- General-Purpose Site-Specific Integration Technology Platform – enables precise genetic modifications
- In Vivo STAR-T Technology Platform – next-generation approach for direct in vivo T-cell reprogramming
- Pipeline: 10+ innovative product candidates spanning hematological tumors, solid tumors, and autoimmune diseases
Regulatory Milestones & Clinical Progress
| Achievement | Status |
|---|---|
| Chinese IND Approvals | 2 granted |
| FDA Designations | 1 Orphan Drug Designation received |
| Lead Product | YTS109 – general-purpose STAR-T core product advancing toward registration clinical trials |
| Therapeutic Areas | Hematological malignancies, solid tumors, autoimmune disorders |
Strategic Investment Rationale
| Investor | Strategic Rationale |
|---|---|
| Loyal Valley Capital | Strong track record in biotechnology investments; expertise in supporting Chinese biotech companies through late-stage clinical development and commercialization |
| Fudan Science and Technology Innovation | Academic-commercial bridge leveraging Fudan University’s research capabilities; focus on cutting-edge cell therapy technologies |
The Chinese cell therapy market is projected to reach RMB 15 billion ($2.1 billion) by 2028, with CAR-T therapies currently dominating but significant opportunity remaining for next-generation approaches like STAR-T that may offer improved safety profiles, manufacturing scalability, and cost-effectiveness.
Competitive Landscape & Market Opportunity
- Current Cell Therapy Market: Dominated by autologous CAR-T products with high costs (RMB 1-2 million per treatment) and complex manufacturing logistics
- STAR-T Differentiation: General-purpose platform potentially enabling allogeneic (“off-the-shelf”) approaches with simplified manufacturing and broader accessibility
- In Vivo Technology Potential: Revolutionary approach that could eliminate ex vivo cell processing entirely, dramatically reducing costs and expanding patient access
- Global Expansion Strategy: FDA Orphan Drug Designation indicates international regulatory pathway planning alongside domestic development
Forward‑Looking Statements
This brief contains forward-looking statements regarding BriSTAR Immunotech’s financing, clinical development plans, regulatory milestones, and commercial prospects. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, competitive developments, and market dynamics in the rapidly evolving cell therapy landscape.-Fineline Info & Tech